drugset / Trial / NCT00500422
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also be studied.
Timeline
- Start
- 2005-01
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 500 mg/m2 | Intravenous |